249results about "Antigen carriers" patented technology

The invention provides stabilizing agents, compositions, methods of manufacturing, and uses thereof. In one aspect, a lipid nanoparticle composition includes: (a) an ionizable lipid; (b) two or more lipids; and (c) a stabilizing agent of formula (I) or formula (II) and methods for preparing the stabilizing agents and the lipid nanoparticle are provided.

The invention provides stabilizing agents, compositions, methods of manufacturing, and uses thereof. In one aspect, a lipid nanoparticle composition including: (a) an ionizable lipid; (b) two or more lipids; and (c) a stabilizing agent of formula (I) and a method for preparing the stabilizing agent and the lipid nanoparticle are provided.

The invention belongs to the technical field of biological medicines, and discloses a recombinant protein and application thereof in preparation of fish vaccines. According to the invention, CP4 protein of nervous necrosis virus of grouper is taken as antigen for vaccine, recombinant Escherichia coli BL21 (pET32a-CP4) capable of expressing the protein is constructed by means of genetic engineering technology, recombinant protein rCP4 is obtained through induced expression, and oxidized single-walled carbon nanotubes are taken as carriers to prepare the grouper immersion vaccine (namely SWCNT-rCP4 vaccine). According to the SWCNT-rCP4 vaccine provided by the invention, the immunization of the grouper can be realized through soaking immunization, the survival rate of the grouper reaches 85% after the grouper is soaked and immunized for 4w and then is infected with NNV, and the immune protection effect is remarkable.

The invention discloses a haemonchus contortus subunit vaccine, and belongs to the field of veterinary vaccines. The subunit vaccine comprises an antigen protein MEP3, an antigen protein AP1, an antigen protein AP8, an antigen protein H11-2, an antigen protein H11-4 and an antigen protein AP5 of galactosylated and modified haemonchus contortus, and the antigen protein MEP3, the antigen protein AP1, the antigen protein AP8, the antigen protein H11-2, the antigen protein H11-4 and the antigen protein AP5 of galactosylated and modified haemonchus contortus. The galactosylation modification of the antigen protein is realized by jointly expressing glycosyl transferase HcGALT of haemonchus contortus and one or more of the proteins in eukaryotic cells. The antigen protein modified by galactosylation in the subunit vaccine is closer to the glycosylation modification of natural protein, and can provide effective immune protection after the goat is infected with haemonchus contortus, and the egg laying rate is reduced by 81.43%. The invention lays a foundation for development of haemonchus contortus subunit vaccines, provides an effective technical means for prevention and treatment of the haemonchus contortus subunit vaccines, and has important application value and popularization prospect.

The invention relates to a monkey pox virus nano vaccine based on an STING agonist and silicon nanoparticles as well as a preparation method and application of the monkey pox virus nano vaccine. The nano vaccine comprises a monkey pox virus antigen, the silicon nanoparticles and the STING agonist, the monkey pox virus antigen is combined to the surface of the silicon nanoparticle through a DogTag-DogCatcher system; the STING agonist is connected to the surface of the monkey pox virus antigen. The monkey pox virus antigen is covalently coupled with the silicon nanoparticles, and the antigen is displayed on the surfaces of the particles in a specific spatial orientation manner, so that the multivalence and accessibility of the antigen are enhanced, the shielding effect of the silicon nanoparticles on epitopes of the antigen is reduced, and the immune response induced by the vaccine is higher than that of a monomer immunogen protein.

Disclosed herein are compositions and methods for eliciting an immune response against both influenza virus and coronavirus. Provided herein are compositions and methods of use thereof, the compositions comprising (a) a coronavirus S (CoV S) glycoprotein in the form of a detergent-core nanoparticle, where the detergent is a non-ionic detergent; (b) at least three hemagglutinin (HA) glycoproteins, where each HA glycoprotein is from a different influenza strain; and (c) a pharmaceutically acceptable buffer.

The methods include selectively reducing or expanding T cells according to the antigenic specificity of the T cells. Therefore, the present invention can be used to reduce or eliminate pathogenic T cells that recognize autoantigens, such as beta cell specific T cells. As such, the present invention can be used to prevent, treat or ameliorate autoimmune diseases such as IDDM. Furthermore, the present invention can be used to expand desirable T cells, such as anti-pathogenic T cells to prevent, treat and / or ameliorate autoimmune diseases.

The present invention relates to the technical field of biomedicine technology and vaccines, and particularly relates to an aluminum nanocrystal delivery system with a surface covered with an Fc affinity protein and a preparation method for a self-assembled particle adjuvant vaccine. An aluminum nanocrystal is used as a carrier, the surface of the aluminum nanocrystal is covered with an Fc affinity protein molecular layer and an antigen molecule, and the antigen of a recombinant Fc Tag specifically binds to an Fc affinity protein, so that antigen self-assembly is realized, a virus-like particle vaccine is formed, and the antigen density is improved. The present vaccine can generate a high-titer specific antibody by inducing a body fluid and cell immunity.

Described herein are covalently modified polypeptide antigens with improved immunogenicity and / or stability, as well as compositions, cells, and methods related to the polypeptide antigens. The polypeptide antigens are covalently conjugated to one or more steroid acid moieties to improve their stability and / or to elicit improved cellular immunity or improved cellular and humoral immunity against the antigens after administration to a subject. The steroid acids include bile acids and bile acid analogs that enhance endosomal trapping of cargo by enhancing the enzymatic cleavage of endosomal membrane- ensheathed sphingomyelin to ceramide and / or endosomal escape. The steroid acid moieties can be preconjugated to a peptide, and the steroid acid-peptide moiety is subsequently conjugated to the polypeptide antigen. The peptide can comprise one or more domains that confer additional functionality to the modified polypeptide antigen.

The present invention provides methods, compositions, systems, and kits comprising nano-satellite complexes and / or serum albumin carrier complexes, which are used for modulating antigen-specific immune response (e.g., enhancing anti-tumor immunity). In certain embodiments, the nano-satellite complexes comprise: a) a core nanoparticle complex comprising a biocompatible coating surrounding a nanoparticle core; b) at least one satellite particle attached to, or absorbed to, the biocompatible coating; and c) an antigenic component conjugated to, or absorbed to, the at least one satellite particle component. In certain embodiments, the complexes further comprise: d) a type I interferon agonist agent. In some embodiments, the serum albumin complexes comprise: a) at least part of a serum albumin protein, b) an antigenic component conjugated to the carrier protein, and c) a type I interferon agonist agent.

The present invention generally relates to an immunogenic construct,useful for redirecting an EBV-existing immune response towards an undesired target cell and / or microorganism,to methods for preparing said conjugate, to a pharmaceutical applications comprising said conjugate, and to medical applications thereof.

Glycotargeting therapeutics are useful in the treatment of transplant rejection, autoimmune disease, food allergy, and immune response against a therapeutic agent.

The present invention pertains to specific bioparticules at the surface of which are expressed multimeric protein. The bioparticles according to the present invention comprise an envelope consisting of a plasma membrane; and at least one type I or II transmembrane fusion protein anchored in said membrane, said fusion protein comprising successively a) a first monomer of a multimeric protein of interest, b) a coiled-coil domain or oligomerization sequence; and c) a domain for anchoring in the plasma membrane, consisting of a transmembrane segment and a cytosolic segment. Fragments a) and b) are exposed at the surface of the bioparticle, and fragment a) is bound to a second monomer of said multimeric protein by means of a bond which is not a peptide bond. The bioparticles according to the present invention can be used in therapy such as immunotherapy. The present invention also pertains to methods for producing such bioparticles.

The present application relates to a dendritic cell-targeted allergen nanovaccine. The present application discloses a nanovaccine which is internally wrapped with an allergen and externally coupled with a dendritic cell targeting molecule. The present application also provides a preparation method and use of the nanovaccine. The nanovaccine can be specifically taken up by dendritic cells, and induce cell tolerance, and is used for specific immunotherapy of allergic diseases.

To provide methods of forming compounds and exemplary stable compounds in the nature of a conjugated compound at refrigerated or room temperature.SOLUTION: The method comprises mixing an antigen and virus particles in a conjugation reaction to form a conjugate mixture, such that the conditions and steps of forming these products allow for use of the conjugate mixture as a vaccine, including but not limited to use as a vaccine against various pathogens including for treatment of diseases caused by novel coronaviruses (including SARS-COV2).SELECTED DRAWING: Figure 1

The invention belongs to the technical field of biological medicine and disease prevention and treatment, and particularly relates to an SSEA4 conjugated virus-like particle anti-cancer vaccine as well as a preparation method and application thereof. Specifically, according to the vaccine, an SSEA4 antigen is efficiently synthesized through a chemical enzyme method, then the SSEA4 antigen is covalently coupled with a virus-like particle (VLP), the SSEA4 antigen and the VLP are combined with a monophosphoryl lipid A adjuvant with high safety, an organism can be induced to generate strong and lasting SSEA4-resistant humoral immune response, the generated antibody can specifically recognize and kill SSEA4 positive tumor cells, and the SSEA4 positive tumor cells can be effectively killed. Meanwhile, good safety is shown in an animal model, a new solution is provided for immunotherapy of SSEA4 positive tumors, and therefore the SSEA4 positive tumor immunotherapy polypeptide has wide application prospects and market value.

The present specification relates to vaccines comprising an mRNA polynucleotide encoding an antigen from an infectious microorganism; and an amphipathic cell penetrating RALA peptide.

The present disclosure generally relates to spherical nucleic acids (SNAs), which are nanostructures having a core surrounded by radial presentation of oligonucleotides that can target multiple classes of immune cells. Methods of making and using nanoparticles are also provided herein. In some aspects, the present disclosure provides spherical nucleic acids (SNAs), comprising: (a) a nanoparticle core; (b) a shell of oligonucleotides bound to the outer surface of the nanoparticle core, the shell of oligonucleotides comprising one or more immunostimulatory oligonucleotides; and (c) a first antigen that is a major histocompatibility complex type I (MHC-I) antigen and a second antigen that is a major histocompatibility complex type II (MHC-II) antigen.

The present invention relates to a vaccine composition including double-stranded DNA delivered into cells via gold nanoparticles, and more particularly, to a vaccine composition characterized in that the double-stranded DNA is derived from a viral, bacterial or cancer gene and expresses an antigen to induce an immune response.

The invention belongs to the technical field of biological medicines, and particularly relates to a universal vaccine constructed by taking lipopolysaccharide or analogues thereof as universal antigens and adjuvants, the vaccine can establish inherent immune memory and adaptive immune memory at the same time after being inoculated, instant quick prevention and control can be realized aiming at sudden epidemic situations, and the immunologic function of the vaccine is improved. And a plurality of diseases can be prevented or treated. Besides, the lipopolysaccharide analogue and an amphiphilic substance are assembled into nanoparticles by utilizing the hydrophobicity of a lipid A structure of the lipopolysaccharide analogue and the hydrophilicity of a glycosyl group, and through ligand modification, the targeting property of the vaccine to antigen presenting cells is improved, and the safety of the lipopolysaccharide or the analogue thereof in application to universal vaccines, adjuvants and medicines is improved.

The disclosure provides modified biotin-binding proteins which can be expressed in soluble form in high yield in bacteria. Also provided are fusion proteins comprising the modified biotin-binding protein and an antigen. The disclosure further provides non-hemolytic variants of alpha-hemolysin from S. aureus and fusion protein comprising non-hemolytic variant of alpha-hemolysin and a biotin-binding domains. Immunogenic compositions comprising the proteins are also disclosed and use of such immunogenic compositions for inducing an immune response or for vaccinating a subject are also disclosed.

The invention discloses a silicon dioxide carrier-based HIV (Human Immunodeficiency Virus) MPER polypeptide nano vaccine as well as a preparation method and application thereof. According to the preparation method, special silicon dioxide nanoparticles are used as a carrier, and MPER polypeptide is connected to the surface of the carrier based on the atomic crystal characteristics (including large specific surface area and certain thermal stability) of the carrier, so that oligomerization of the polypeptide is reduced, and the effective antigen immunity is improved. In order to further realize the enrichment of the antigen, the MPER polypeptide is treated by adopting a four-limb peptide mode, so that a more stable system can be formed after the MPER polypeptide is coupled with the nanoparticles. Based on a stable polypeptide structure and chemical properties thereof, the polypeptide has better rigidity, the variability is reduced, the antigen quality is ensured, and the antigen activity is improved. The finally obtained nano antigen can effectively enter the body to induce a high-titer neutralizing antibody, and has great significance for controlling HIV-1 transmission.

The present invention generally relates to methods and composition matters for delivery of a cargo to a living cell over producing immunoproteasomes. More specifically the invention disclosed is a molecular construct that delivers a cargo, for diagnostic or therapeutic purposes, to a living cell. Methods of use and composition matters are within the scope of this disclosure.

Disclosed herein are nanoparticles suitable for use in vaccines. The nanoparticles present antigens from pathogens surrounded with and associated to a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

The present invention relates to a non-injectable drug delivery system using mucoadhesive nanoparticles, and to mucoadhesive nanoparticles and a method for producing the same, which prevent deformation of the nanoparticles due to mucosal moisture, etc., and strengthen mucoadhesiveness to prevent loss by binding a mucoadhesive polymer to the surface of the nanoparticles. The present invention also relates to a composition for maturing antigen-presenting cells, a composition for treating infectious diseases, and a composition for treating cancer, which comprise the mucoadhesive nanoparticles. The present invention also relates to mucoadhesive nanoparticles loaded with immune active substances (such as antigens and adjuvants) for cancer treatment and immunotherapy based on antigen-presenting cells including dendritic cells (DCs), and a composition for immune anti-cancer treatment comprising the same.

Disclosed herein are coronavirus (CoV) Spike (S) polypeptides, including naturally and non-naturally occurring polypeptides, and nanoparticles and immunogenic compositions comprising the same, which are useful for stimulating immune responses against various SARS-CoV-2 strains. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

A targeted delivery system carrying a whole cell fraction, which relates to the technical field of immunotherapy, is described. The targeted delivery system is a nanoscale or microscale particle having a targeting head on its surface. The particle is loaded with a whole cell fraction of cancer cells or cancer tissues, the whole cell fraction being the water-soluble and water-insoluble components of all cells in the cell or tissue, the water-insoluble components being soluble with a solubilizing agent. The targeting head binds to molecules on the surface of specific cells or tissues, thereby helping the particle enter the cell or tissue. The targeted delivery system solubilizes the water-insoluble components using a specific solubilizing agent, making it soluble in aqueous solution. This allows the preparation of a cancer vaccine by combining the water-soluble components in the cancer cells or tissues with the whole cell antigens of the water-insoluble components. At the same time, the system is equipped with a targeting head capable of targeting antigen-presenting cells, thereby improving the efficiency of phagocytosis by antigen-presenting cells in an active targeting manner, further enhancing the efficacy of cancer prevention or treatment.

The present invention discloses a polysaccharide conjugate vaccine and a preparation method and application thereof. The polysaccharide conjugate vaccine comprises (a) a polysaccharide; (b) a polypeptide that can bind to a major histocompatibility complex class II molecule; and (c) a plant virus or a bacteriophage; wherein the polysaccharide and the polypeptide are covalently linked to form a polysaccharide-polypeptide conjugate, and the polysaccharide-polypeptide conjugate is covalently bound to the outer surface of the plant virus or the bacteriophage. The polysaccharide conjugate vaccine of the present invention can effectively improve the defect of low immunogenicity of the antigen polysaccharide, and can produce the effect of preventing fungal or bacterial infection after immunizing the body.

The present invention relates to a liposomal vaccine composition comprising a peptide antigen displayed on the surface of a liposome; a peptide comprising a T cell epitope; and an adjuvant, wherein the peptide antigen has the structure: X 1 -X 2 -X 3 -EX 4 -X 5 -PVDPDNEX 6 wherein E is glutamic acid, P is proline, V is valine, D is aspartic acid, and X is a nucleotide sequence consisting essentially of the structure 1 is optionally present and, if present, is G, where G is glycine; X 2 is optional and, if present, is G, where G is as defined above; X 3 is L, K, or S, where L is leucine, K is lysine, and S is serine; X 4 is D, K, or S, where D, K, and S are as defined above; X 5 is M, where M is methionine or methionine sulfoxide; X 6 is A, K, or S, where A is alanine, K and S are as defined above; 3 -EX 4 -X 5 -PVDPDNEX 6 is not LEDMPVDPDNEA and contains 1 to 5 amino acid differences compared to the amino acid sequence GILEDMPVDPDNEA; and the peptide antigen is the dipeptide YE. 6 where Y is tyrosine and E is as defined above.

Methods for stabilizing a liquid vaccine for mucosal use are provided. In certain aspects, the methods may include combining a liquid comprising at least one antigen or antigen encoding composition with a petrolatum carrier.